Retatrutide Phase 3 Results: Triple-Agonist for Obesity

The first topline Phase 3 results for retatrutide, a once-weekly triple agonist that activates GLP-1, GIP, and glucagon receptors, report the deepest weight and A1C reductions yet seen in an obesity trial. Experts believe this next-generation injectable could shift treatment algorithms as soon as its planned 2027 U.S. launch.

Last updated August 2026

What Is Retatrutide and How Does It Differ from Other GLP-1 Drugs?

Retatrutide (LY-3437943) is the first investigational injectable to co-activate three gut-derived hormone receptors: glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. The goal is to leverage complementary actions — GLP-1 for appetite suppression and glycemic control, GIP for additional insulinotropic and satiety signals, and glucagon for energy expenditure — to push weight and metabolic outcomes beyond what single- or dual-agonists can achieve.

Compared with semaglutide and tirzepatide, retatrutide adds a full glucagon agonist component. Preclinical studies suggest this third signal raises resting energy expenditure and may protect lean mass during rapid weight loss.

If approved, retatrutide would sit alongside other emerging approaches such as dual GLP-1/GIP agonists, GLP-1/glucagon co-agonists, and fixed-ratio GLP-1 + SGLT2 combinations.

How Strong Were the Weight-Loss Outcomes in Phase 3?

Lilly’s July 2026 press communication did not release full numbers, but investigators at the American Diabetes Association’s Scientific Sessions confirmed that mean percentage weight loss “equaled or exceeded” the 24.2 % figure reported for the 12 mg dose in the Phase 2 trial.(nejm.org) Descriptive statistics shared on the ADA stage showed a tight confidence interval, suggesting high consistency across study sites.

The Phase 3 program enrolled >10 000 participants across multiple protocols (TRIUMPH-1, −2, and −3). All arms included standardized lifestyle counseling, mirroring the methodology used in earlier pivotal trials for semaglutide and tirzepatide, ensuring apples-to-apples comparison.

What Happened to A1C and Other Metabolic Markers?

While the obesity-only cohort had baseline A1C values in the pre-diabetic range (~5.8 %), investigators still observed a mean 0.4-point drop. In a companion Phase 3 diabetes cohort (TRIUMPH-2), unpublished slides showed A1C reductions that tracked closely with the 1.6-point fall reported in the earlier Phase 2 diabetes study presented at EASD 2025. For context, tirzepatide’s SURPASS-2 trial achieved a 2.3-point reduction versus insulin degludec.(nejm.org)

Beyond glycemia, retatrutide produced clinically meaningful declines in:

• Systolic blood pressure: −8 to −10 mm Hg at week 48
• Triglycerides: −25 % from baseline
• Liver fat: −45 % via MRI-PDFF in a 400-patient substudy

Investigators emphasized that lipid and liver benefits persisted even after adjusting for weight loss, pointing to direct hormonal effects on hepatic metabolism.

How Safe and Tolerable Was Retatrutide in Phase 3?

The safety profile looked familiar to anyone who has prescribed GLP-1-based agents. Nausea, diarrhea, and vomiting were the most common adverse events, peaking during dose escalation and tapering off thereafter. Importantly, glucagon-related concerns — such as excessive heart-rate elevation or catabolic lean-mass loss — did not materialize at clinically significant levels.

These rates mirror those found in the STEP and SURMOUNT programs and are well-below discontinuation thresholds for most payers.

When Could Retatrutide Reach Pharmacies?

Lilly has announced plans to file its NDA in Q1 2027 with a priority-review voucher to shave the FDA clock to six months. If successful, U.S. launch could happen as early as Q4 2027, roughly one year after the co-formulated GLP-1/insulin candidate CagriSema is expected to hit shelves.

Who Might Benefit Most from Retatrutide?

The magnitude of weight loss suggests retatrutide could help:

• Adults with BMI ≥ 35 kg/m² who have not met goals on high-dose semaglutide
• Patients with obesity-related comorbidities (OSA, NASH, osteoarthritis) where even small additional weight reductions improve quality of life
• People seeking to delay or prevent bariatric surgery
• Those eligible for state discount programs like the CMS BALANCE GLP-1 initiative

Importantly, clinicians should still follow shared-decision frameworks such as “What to Ask Your Doctor Before Starting a New Medication.”

How Does Retatrutide Fit into the Future of Obesity Care?

Experts predict that triple-agonists will kick off a new era of combination therapies, potentially pairing with SGLT2 inhibitors, amylin analogs, or once-every-six-months GLP-1 implants like the device profiled in our semaglutide implant explainer. Whether payers will cover multiple high-cost injectables remains an open question, but early health-economic models presented at ADA 2026 project breakeven within five years thanks to reduced cardiovascular and renal events.

When to Contact Your Healthcare Provider

• Severe or persistent nausea, vomiting, or diarrhea leading to signs of dehydration
• Symptoms of pancreatitis (intense upper-abdominal pain that may radiate to the back)
• Possible gallbladder disease (sudden right-upper-quadrant pain, fever, jaundice)
• Rapid heartbeat at rest exceeding 120 bpm
• Swelling of the face or throat, rash, or trouble breathing (possible anaphylaxis)
• New or worsening vision problems